Concepedia

Matthew Lindon

ML

Statistics

Publications

17

Citations

1.6K

H-Index

16

Active since

2004

Affiliations

GlaxoSmithKline (United Kingdom)(Current)

GlaxoSmithKline (Germany)

University of Strathclyde

Molecular Discovery (United Kingdom)

GlaxoSmithKline (United States)

Matthew Lindon is an author at GlaxoSmithKline (United Kingdom) specializing in bromodomain inhibition, drug discovery, and bromodomain proteins.

ORCID

Publications per year

2004–2022

17

Publications

17

Selective targeting of BD1 and BD2 of the BET proteins in cancer and immunoinflammation

Omer Gilan, Inmaculada Rioja, Kathy Knezevic et al. · Science · 2020 · 428 citations · Full text

, , +13

Discovery of I-BRD9, a Selective Cell Active Chemical Probe for Bromodomain Containing Protein 9 Inhibition

Natalie H. Theodoulou, Paul Bamborough, Andrew J. Bannister et al. · Journal of Medicinal Chemistry · 2015 · 234 citations · Full text

, , +15

Discovery and Characterization of GSK2801, a Selective Chemical Probe for the Bromodomains BAZ2A and BAZ2B

Peiling Chen, A. Chaikuad, Paul Bamborough et al. · Journal of Medicinal Chemistry · 2015 · 161 citations · Full text

, , +15

Discovery of Tetrahydroquinoxalines as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with Selectivity for the Second Bromodomain

Robert P. Law, Stephen J. Atkinson, Paul Bamborough et al. · Journal of Medicinal Chemistry · 2018 · 118 citations · Full text

, , +17

The Commonly Used PI3-Kinase Probe LY294002 Is an Inhibitor of BET Bromodomains

Antje Dittmann, Thilo Werner, Chun‐wa Chung et al. · ACS Chemical Biology · 2013 · 114 citations · Full text

, , +13

1–5 of 17